ReferenceRRK5720

ALT GIST (EORTC 1321)

A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Research Summary

Research Overview
Project Status Open
Proposed End Date 30/04/2021
Study Run through CRF? Yes
Target number of patients agreed to recruit 1
Recruitment so far 0